Zacks Investment Research
04 Nov 2026, 16:41 UTC · 1d ago
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Impact · against what's priced in
Lifyorli's faster-than-expected ramp-up provides a positive catalyst for Corcept, supporting the bull case for high peak revenues that the market has not yet fully priced in. However, a slight miss in legacy Korlym sales and the company's decision to maintain conservative full-year guidance temper the upside.
- CORT+0.40
Challenges what's priced in
- The price assumes
The bull case that Lifyorli's U.S. peak revenue will exceed $1 billion and drive a 44%+ sustained revenue growth rate is not fully paid for
Lifyorli's $91.4 million Q3 revenue represents a 92% sequential increase and a beat against model estimates, providing concrete evidence for the high-growth trajectory the market is currently discounting.
What CORT's price assumes · Sep 14
